Current Oncology Reports

, Volume 2, Issue 6, pp 529–538

Therapy for childhood acute myeloid leukemia: Role of allogeneic bone marrow transplantation

  • Esteban Abella
  • Yaddanapudi Ravindranath


Acute myeloid leukemia (AML) has one of the lowest survival rates of childhood cancers. The first significant improvement in AML therapy started with the introduction of the now standard regimen of 3 days of anthracyclines and 7 days of cytarabine (Ara-C), the so-called 3+7 combinations. Several different therapeutic approaches have been taken in attempts to improve the outcome, including intensification of therapy both for remission induction and in the postremission phase. Intensification of postremission therapy included multiple courses of high-dose chemotherapy and/or myeloablative therapy followed by stem-cell rescue from either allogeneic or autologous sources. Furthermore, risk-tailored therapy is now possible, by cytogenetic risk stratification, promptness of remission induction, and identification of distinct clinical subgroups such as children with Down syndrome. This approach is rapidly changing potential therapeutic strategies for children with AML. It is in this changing mileu that we address the proper role of stem-cell transplantation, a modality that is changing (like chemotherapy) with expanding stem-cell sources and approaches to decrease transplant-related toxicity.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Novakovic B: U.S. childhood cancer survival, 1973–1987. Med Pediatr Oncol 1994, 23:480–486.PubMedCrossRefGoogle Scholar
  2. 2.
    Weinstein HJ, Mayer RJ, Rosenthal DS, et al.: Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980, 303:473–478.PubMedCrossRefGoogle Scholar
  3. 3.
    Ravindranath Y, Yeager AM, Chang MN, et al.: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for ccute myeloid leukemia in childhood. N Engl J Med 1996, 334:1428–1434.PubMedCrossRefGoogle Scholar
  4. 4.
    Woods WG, Kobrinsky N, Buckley JD, et al.: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. Blood 1996, 87:4979–4989.PubMedGoogle Scholar
  5. 5.
    Creutzig U, Harbott J, Sperling C, et al.: Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995, 86:3097–3108.PubMedGoogle Scholar
  6. 6.
    Burnett AK, Goldstone AH, Stevens RM, et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet 1998, 351:700–708. Reports results of an adult and pediatric study (MRC AML10) comparing autograft with no further therapy after four cycles of chemotherapy.PubMedCrossRefGoogle Scholar
  7. 7.
    Lie SO, Jonmundsson G, Mellander L, et al.: A populationbased study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down’s syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol 1996, 94:82–88.PubMedCrossRefGoogle Scholar
  8. 8.
    Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999, 341:1051–1062.PubMedCrossRefGoogle Scholar
  9. 9.
    Ravindranath Y, Abella E, Krischer JP, et al.: Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992, 80:2210–2214.PubMedGoogle Scholar
  10. 10.
    Degos L, Dombret H, Chomienne C, et al.: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85:2643–2653.PubMedGoogle Scholar
  11. 11.
    Bennett JM, Catovsky D, Daniel MT, et al.: Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620–625.PubMedGoogle Scholar
  12. 12.
    Cheson BD, Cassileth PA, Head DR, et al.: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990, 8:813–819.PubMedGoogle Scholar
  13. 13.
    Raimondi SC, Chang MN, Ravindranath Y, et al.: Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999, 94:3707–3716. Review of cytogenetic and clinical features with outcome in children treated in a randomized chemotherapy versus autograft study, POG 8821.PubMedGoogle Scholar
  14. 14.
    Head DR: Revised classification of acute myeloid leukemia. Leukemia 1996, 10:1826–1831.PubMedGoogle Scholar
  15. 15.
    Zipursky A, Thorner P, De Harven E, et al.: Myelodysplasia and acute megakaryoblastic leukemia in Down’s syndrome. Leuk Res 1994, 18:163–171.PubMedCrossRefGoogle Scholar
  16. 16.
    Mayer RJ, Davis RB, Schiffer CA, et al.: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994, 331:896–903.PubMedCrossRefGoogle Scholar
  17. 17.
    Bishop JF, Matthews JP, Young GA, et al.: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710–1717.PubMedGoogle Scholar
  18. 18.
    Wiernik PH, Banks PL, Case DC Jr, et al.: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992, 79:313–319.PubMedGoogle Scholar
  19. 19.
    Ravindranath Y, Steuber CP, Krischer J, et al.: High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991, 9:572–580.PubMedGoogle Scholar
  20. 20.
    Zittoun RA, Mandelli F, Willemze R, et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995, 332:217–223.PubMedCrossRefGoogle Scholar
  21. 21.
    Nugent M, Horowitz M: Pediatric AML analysis from the International Bone Marrow Transplant Registry and Autologous Bone Marrow Transplant Registry, 1999.Google Scholar
  22. 22.
    Gorin NC, Labopin M, Fouillard L, et al.: Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia: a study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996, 18:111–117.PubMedGoogle Scholar
  23. 23.
    Klingebiel T, Pession A, Paolucci P, et al.: Autologous versus allogeneic BMT in AML: the European experience. Report of the EBMT-Pediatric Diseases Working Party. Bone Marrow Transplant 1996, 18(suppl 2):49–52.PubMedGoogle Scholar
  24. 24.
    Amadori S, Testi AM, Arico M, et al.: Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia: the Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993, 11:1046–1054.PubMedGoogle Scholar
  25. 25.
    Stevens RF, Hann IM, Wheatley K, et al.: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council’s 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998, 101:130–140.PubMedCrossRefGoogle Scholar
  26. 26.
    Webb DK, Wheatley K, Harrison G, et al.: Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999, 13:25–31 Reports on outcome of a randomized trial of autograft versus no further therapy in childhood AML, updating the initial results.PubMedCrossRefGoogle Scholar
  27. 27.
    Feig SA, Lampkin B, Nesbit ME, et al.: Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Children’s Cancer Group. Bone Marrow Transplant 1993, 12:65–71.PubMedGoogle Scholar
  28. 28.
    Michel G, Leverger G, Leblanc T, et al.: Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission: a prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996, 17:191–196.PubMedGoogle Scholar
  29. 29.
    Creutzig U, Bender-Gotze C, Klingebiel T, et al.: Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies-matched pair analysis. Klin Padiatr 1992, 204:246–252.PubMedCrossRefGoogle Scholar
  30. 30.
    Clift RA, Buckner CD, Appelbaum FR, et al.: Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992, 10:1723–1729.PubMedGoogle Scholar
  31. 31.
    Dini G, Cornish JM, Gadner H, et al.: Bone marrow transplant indications for childhood leukemias: achieving a consensus. The EBMT Pediatric Diseases Working Party. Bone Marrow Transplant 1996, 18(suppl 2):4–7.PubMedGoogle Scholar
  32. 32.
    Stahnke K, Boos J, Bender-Gotze C, et al.: Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998, 12:1534–1538. Report of relationship between duration of first remission and achievement of second clinical response and its impact on survival.PubMedCrossRefGoogle Scholar
  33. 33.
    Ringden O, Labopin M, Gluckman E, et al.: Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1997, 19:963–968.PubMedCrossRefGoogle Scholar
  34. 34.
    Cassileth PA, Harrington DP, Appelbaum FR, et al.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649–1656.PubMedCrossRefGoogle Scholar
  35. 35.
    Rubin CM, Mick R, Johnson FL: Bone marrow transplantation for the treatment of haematological disorders in Down’s syndrome: toxicity and outcome. Bone Marrow Transplant 1996, 18:533–540.PubMedGoogle Scholar
  36. 36.
    Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998, 92:2322–2333.PubMedGoogle Scholar
  37. 37.
    Chang M, Raimondi SC, Ravindranath Y, et al.: Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia: univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG Study 8891). Leukemia 2000, 14:1201–1207.PubMedCrossRefGoogle Scholar
  38. 38.
    Creutzig U, Zimmermann M, Ritter J, et al.: Definition of a standard-risk group in children with AML. Br J Haematol 1999, 104:630–639. BFM analysis of risk factors in over 400 children with AML.PubMedCrossRefGoogle Scholar
  39. 39.
    Dharan B MN, King R: National Marrow Donor Program. Pediatric AML NMDP Program Statistics. Minneapolis MN: June 30, 1999.Google Scholar
  40. 40.
    Ladenstein R, Peters C, Gadner H: The present role of bone marrow and stem cell transplantation in the therapy of children with acute leukemia. Ann N Y Acad Sci 1997, 824:38–64.PubMedCrossRefGoogle Scholar
  41. 41.
    Blaise D, Maraninchi D, Archimbaud E, et al.: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 1992, 79:2578–2582.PubMedGoogle Scholar
  42. 42.
    Helenglass G, Powles RL, McElwain TJ, et al.: Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant 1988, 3:21–29.PubMedGoogle Scholar
  43. 43.
    Ringden O, Labopin M, Tura S, et al.: A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996, 93:637–645.PubMedCrossRefGoogle Scholar
  44. 44.
    Grigg AP, Szer J, Beresford J, et al.: Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999, 107:409–418.PubMedCrossRefGoogle Scholar
  45. 45.
    Gale RP, Horowitz MM: Graft-versus-leukemia in bone marrow transplantation: the Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1990, 6(suppl 1):94–97.PubMedGoogle Scholar
  46. 46.
    Powles R, Singhal S, Treleaven J, et al.: Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998, 91:3481–3486.PubMedGoogle Scholar
  47. 47.
    Elmaagacli AH, Beelen DW, Trenn G, et al.: Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:771–777.PubMedCrossRefGoogle Scholar
  48. 48.
    Kolb HJ: Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation: EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 74:321–329.Google Scholar
  49. 49.
    Singhal S, Powles R, Kulkarni S, et al.: Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versushost disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma 1999, 32:505–512. Review of donor leukocyte infusions for relapse after BMT.PubMedGoogle Scholar
  50. 50.
    Kumar L: Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994, 12:1710–1717.PubMedGoogle Scholar
  51. 51.
    de la Rubia J, Sanz GF, Martin G, et al.: Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplant 1996, 18:1167–1173.PubMedGoogle Scholar
  52. 52.
    Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756–763 Early report of a non-meloablative allograft study with the focus on allo-reactivity and GVL.PubMedGoogle Scholar
  53. 53.
    Champlin R, Khouri I, Giralt S: Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. J Clin Apheresis 1999, 14:45–49.PubMedCrossRefGoogle Scholar
  54. 54.
    Ortega JJ, Olive T, Diaz de Heredia C, et al.: Allogeneic and autologous bone marrow transplantation in AML in first remission: the Spanish experience. Bone Marrow Transplant 1996, 18(suppl 2):53–58.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Esteban Abella
    • 1
  • Yaddanapudi Ravindranath
    • 1
  1. 1.Children’s Hospital of Michigan, Wayne State UniversityBarbara Ann Karmanos Cancer InstituteDetroitUSA

Personalised recommendations